0001225208-24-001597.txt : 20240205 0001225208-24-001597.hdr.sgml : 20240205 20240205183744 ACCESSION NUMBER: 0001225208-24-001597 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240205 FILED AS OF DATE: 20240205 DATE AS OF CHANGE: 20240205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MUSSALLEM MICHAEL A CENTRAL INDEX KEY: 0001204551 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-15525 FILM NUMBER: 24597398 MAIL ADDRESS: STREET 1: C/O EDWARDS LIFESCIENCES CORP STREET 2: ONE EDWARDS WAY CITY: IRVINE STATE: CA ZIP: 92614 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Edwards Lifesciences Corp CENTRAL INDEX KEY: 0001099800 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 364316614 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE EDWARDS WAY CITY: IRVINE STATE: CA ZIP: 92614 BUSINESS PHONE: 9492502500 MAIL ADDRESS: STREET 1: ONE EDWARDS WAY CITY: IRVINE STATE: CA ZIP: 92614 FORMER COMPANY: FORMER CONFORMED NAME: EDWARDS LIFESCIENCES CORP. DATE OF NAME CHANGE: 20090225 FORMER COMPANY: FORMER CONFORMED NAME: EDWARDS LIFESCIENCES CORP DATE OF NAME CHANGE: 20000203 FORMER COMPANY: FORMER CONFORMED NAME: CVG CONTROLLED INC DATE OF NAME CHANGE: 19991126 4 1 doc4.xml X0508 4 2024-02-05 0001099800 Edwards Lifesciences Corp EW 0001204551 MUSSALLEM MICHAEL A ONE EDWARDS WAY IRVINE CA 92614 1 1 Common Stock 2024-02-05 4 M 0 29350.0000 36.7500 A 33835.8200 D Common Stock 2024-02-05 4 S 0 1000.0000 89.6100 D 32835.8200 D Common Stock 2024-02-05 4 S 0 6422.0000 88.6300 D 26413.8200 D Common Stock 2024-02-05 4 S 0 9761.0000 86.4400 D 16652.8200 D Common Stock 2024-02-05 4 S 0 12167.0000 87.5500 D 4485.8200 D Common Stock 4038377.0000 I By Living Trust Employee Stock Option (Right to Acquire) 36.7500 2024-02-05 4 M 0 29350.0000 0.0000 D 2017-06-11 2024-05-10 Common Stock 29350.0000 88050.0000 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. This transaction was executed in multiple trades at prices ranging from $89.390 to $90.080. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $88.210 to $89.200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $86.100 to $87.070. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $87.110 to $88.105. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Linda J. Park, Attorney-in-Fact 2024-02-05